Valsartan

Novartis Pharma S.A.E confirms all company products in Egypt unaffected by valsartan recall

Cairo, July 31, 2018 – Novartis Pharma S.A.E (Novartis Pharma) confirms that none of its products in Egypt are affected by the decision to recall certain products containing valsartan

Read more about Novartis Pharma S.A.E confirms all company products in Egypt unaffected by valsartan recall

To report an adverse event or any drug related issues concerning Novartis medicianal products; please contact Novartis Patient Safety: Tel: +202 22861000 - Press 3 for reporting an adverse event. Fax: 002 02 26031702. E-mail: [email protected]

For safety labels, please click here and follow the below steps:

Enter the name of the product in the search field
Select the result “Human medicine European public assessment report (EPAR)”
In product information section, click the link “EPAR- product information’ to download the last updated section of the EU SmPC